Sensitivity of urinary mesothelin in patients with malignant mesothelioma

Journal of Thoracic Oncology

Volumn 5, Issue 9, 2010, Pages 1461-1466

  Creaney, Jenette ^a,b   Musk, Arthur W ^a,b   Robinson, Bruce W S ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Biomarkers; Diagnosis; Mesothelin; Mesothelioma; SMRP

Indexed keywords

ASBESTOS; BIOLOGICAL MARKER; CREATININE; MESOTHELIN;

ADULT; AGED; ARTICLE; ASBESTOSIS; CONTROLLED STUDY; CREATININE URINE LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; FEMALE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PLEURA DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS;

EID: 77956261304     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e392d7     Document Type: Article

References (26)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603.
2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
3. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-155
4. Hasani A, Alvarez JM, Wyatt JM, et al. Outcome for patients with malignant pleural mesothelioma referred for trimodality therapy in Western Australia. J Thorac Oncol 2009;4:1010-1016.
5. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616.
6. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothe-lin levels for the diagnosis of malignant mesothelioma. Chest 2007;132: 1239-1246.
7. Bolduc S, Lacombe L, Naud A, et al. Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J 2007;1:377-381.
8. Konety B, Lotan Y. Urothelial bladder cancer: biomarkers for detection and screening. BJU Int 2008;102:1234-1241.
9. Badgwell D, Lu Z, Cole L, et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 2007;106:490-497.
10. Yamaguchi N, Hattori K, Oh-eda M, et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 1994;269:805-808.
11. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 1995;270: 21984-21990.
12. Muminova ZE, Strong TV, Shaw DR. Characterization of human me-sothelin transcripts in ovarian and pancreatic cancer. BMC Cancer 2004;4:19.
13. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunother-apy. Clin Cancer Res 2004;10:3937-3942.
14. Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-1020.
15. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999;96: 11531-11536.
16. Kagan E, Brody A. Immunopathology of asbestos-related lung disease. In R Kradin, B Robinson (Eds.), Immunopathology of Lung Disease. Boston: Butterworth-Heinemann, 1996. Pp. 421-444.
17. Spurzem J, Rennard S. Immunopathology of idiopathic pulmonary fibrosis. In R Kradin, B Robinson (Eds.), Immunopathology of Lung Disease. Boston: Butterworth-Heinemann, 1996. Pp. 165-190.
18. Robinson B. Sarcoidosis. In R Kradin, B Robinson (Eds.), Immunopa-thology of Lung Disease. Boston: Butterworth-Heinemann, 1996. Pp. 165-190.
19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999;130:461-470.
20. Creaney J, McLaren BM, Stevenson S, et al. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer 2001;84:52-56.
21. Manning LS, Whitaker D, Murch AR, et al. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 1991;47:285-290.
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845.
23. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyper-plasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 1998;110:397-404.
24. Hollevoet K, Bernard D, De Geeter F, et al. Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem 2009;55:1431-1433.
25. Park EK, Thomas PS, Creaney J, et al. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 2010;48:869-874.
26. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-9198.